SEC Form 4 · accession 0000899243-18-009444
Q32 Bio Inc. · QTTB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001661998
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 2, 2018 | C | 1,979,226 | $0.00 | A | 1,979,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2 | — | Apr 2, 2018 | C | 1,979,226 | D | — | — | Common Stock | 1,979,226 | 0 | D |
Explanation of responses
- F1The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Common Stock held directly by NIBRI.
- F2Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.